Learn how physicians join pharmaceutical advisory boards, how much they pay, and how doctors can…
Sermo Physician Resources
Pharmaceuticals
Journavx FDA approval: non-opioid pain management in 2026
Journavx (suzetrigine) is the first new pain drug class in 20 years. Explore trial results,…
How AI is reshaping drug development in 2026: discovery to delivery
On Sermo, physicians explore how AI is transforming drug development, from rational design to predictive…
Lepodisiran: A new cholesterol drug raising big questions
Explore physician reactions to Lepodisiran, an RNA-based cholesterol drug showing a 94% reduction in Lp(a).…
85% of doctors say RNA-based drug lepodisiran could be a game-changer
Doctors weigh in on lepodisiran, an RNA-based drug that slashes stealth cholesterol (Lp(a)) by 94%.…